Index
1 Pulmonary Arterial Hypertension (PAH) Medicine Market Overview
1.1 Pulmonary Arterial Hypertension (PAH) Medicine Product Overview
1.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Segment by Type
1.2.1 Calcium Channel Blockers
1.2.2 Novel Targeted Drugs
1.2.3 Other
1.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Type
1.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Overview by Type (2018-2029)
1.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Type (2018-2023)
2 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Competition by Company
2.1 Global Top Players by Pulmonary Arterial Hypertension (PAH) Medicine Sales (2018-2023)
2.2 Global Top Players by Pulmonary Arterial Hypertension (PAH) Medicine Revenue (2018-2023)
2.3 Global Top Players by Pulmonary Arterial Hypertension (PAH) Medicine Price (2018-2023)
2.4 Global Top Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pulmonary Arterial Hypertension (PAH) Medicine Market Competitive Situation and Trends
2.5.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Pulmonary Arterial Hypertension (PAH) Medicine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Medicine as of 2022)
2.7 Date of Key Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Medicine Market
2.8 Key Manufacturers Pulmonary Arterial Hypertension (PAH) Medicine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pulmonary Arterial Hypertension (PAH) Medicine Status and Outlook by Region
3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Region
3.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2018-2023)
3.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Region (2018-2023)
3.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Region
3.3.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2024-2029)
3.3.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Region (2024-2029)
3.3.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Pulmonary Arterial Hypertension (PAH) Medicine by Application
4.1 Pulmonary Arterial Hypertension (PAH) Medicine Market Segment by Application
4.1.1 Secondary Pulmonary Hypertension (SPH)
4.1.2 Primary Pulmonary Hypertension (PPH)
4.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size by Application
4.2.1 Global Pulmonary Arterial Hypertension (PAH) Medicine Market Size Overview by Application (2018-2029)
4.2.2 Global Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales Breakdown by Application (2018-2023)
5 North America Pulmonary Arterial Hypertension (PAH) Medicine by Country
5.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Country
5.1.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2018-2023)
5.1.3 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2018-2023)
5.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Country
5.2.1 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2024-2029)
5.2.2 North America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2024-2029)
6 Europe Pulmonary Arterial Hypertension (PAH) Medicine by Country
6.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Country
6.1.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2018-2023)
6.1.3 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2018-2023)
6.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Country
6.2.1 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2024-2029)
6.2.2 Europe Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2024-2029)
7 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine by Region
7.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Region
7.1.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Region
7.2.1 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Region (2024-2029)
8 Latin America Pulmonary Arterial Hypertension (PAH) Medicine by Country
8.1 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Country
8.1.1 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2018-2023)
8.2 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Country
8.2.1 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2024-2029)
9 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine by Country
9.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Historic Market Size by Country
9.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Forecasted Market Size by Country
9.2.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Medicine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Medicine Products Offered
10.1.5 Pfizer Recent Development
10.2 Gilead Sciences
10.2.1 Gilead Sciences Company Information
10.2.2 Gilead Sciences Introduction and Business Overview
10.2.3 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Gilead Sciences Pulmonary Arterial Hypertension (PAH) Medicine Products Offered
10.2.5 Gilead Sciences Recent Development
10.3 Eli Lilly
10.3.1 Eli Lilly Company Information
10.3.2 Eli Lilly Introduction and Business Overview
10.3.3 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Eli Lilly Pulmonary Arterial Hypertension (PAH) Medicine Products Offered
10.3.5 Eli Lilly Recent Development
10.4 Actelion Pharmaceuticals
10.4.1 Actelion Pharmaceuticals Company Information
10.4.2 Actelion Pharmaceuticals Introduction and Business Overview
10.4.3 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Medicine Products Offered
10.4.5 Actelion Pharmaceuticals Recent Development
10.5 United Therapeutics Corporation
10.5.1 United Therapeutics Corporation Company Information
10.5.2 United Therapeutics Corporation Introduction and Business Overview
10.5.3 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 United Therapeutics Corporation Pulmonary Arterial Hypertension (PAH) Medicine Products Offered
10.5.5 United Therapeutics Corporation Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pulmonary Arterial Hypertension (PAH) Medicine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pulmonary Arterial Hypertension (PAH) Medicine Industrial Chain Analysis
11.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Dynamics
11.4.1 Pulmonary Arterial Hypertension (PAH) Medicine Industry Trends
11.4.2 Pulmonary Arterial Hypertension (PAH) Medicine Market Drivers
11.4.3 Pulmonary Arterial Hypertension (PAH) Medicine Market Challenges
11.4.4 Pulmonary Arterial Hypertension (PAH) Medicine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pulmonary Arterial Hypertension (PAH) Medicine Distributors
12.3 Pulmonary Arterial Hypertension (PAH) Medicine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer